Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study

Citations Over TimeTop 10% of 2014 papers

Abstract

YORA patients were more frequently ACPA-positive than LORA patients. LORA was more often associated with erosions, higher Larsen scores, higher disease activity and higher HAQ scores at baseline. Nevertheless, YORA was treated earlier with DMARDs, whilst LORA was more often treated with corticosteroids and less often with DMARDs in early-stage disease. These findings could have implications for the development of comorbidities.

Related Papers

• → Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense(2003)224 cited
• → Erythrocyte Sedimentation Rate, C-Reactive Protein, or Rheumatoid Factor Are Normal at Presentation in 35%–45% of Patients with Rheumatoid Arthritis Seen Between 1980 and 2004: Analyses from Finland and the United States(2009)142 cited
• → Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects(2006)55 cited
• → Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy(2004)35 cited
• → A retrospective case-control hospital based study on the diagnostic utility of anti-cyclic citrullinated peptide antibodies in comparison with rheumatoid factor, C-reactive protein and erythrocyte sedimentation rate as a diagnostic inflammatory biomarker(2019)1 cited